
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
October 14, 2016
Potentially anticompetitive practices in the pharmaceutical industry are among topics to be discussed at a global meeting on competition next week in Geneva, Switzerland. Referring to agreements which occur when a patent holder compensates a competitor to delay or abandon the launch of a generic drug, United Nations Conference on Trade and Development (UNCTAD) economist Ebru Gokce commented: "We're not questioning the merit of patent protection. We're questioning the anti-competitive nature of practices, such as pay-for-delay agreements, that prolong market exclusivity." The



